Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer

Breast Cancer Research and Treatment

Volumn 87, Issue 1, 2004, Pages 23-31

  Tsuji, Naoki ^a   Furuse, Kaori ^a   Asanuma, Koichi ^a   Furuya, Momoko ^a   Kondoh, Kei ^a   Kamagata, Chinatsu ^a   Sasaki, Masateru ^a   Kobayashi, Daisuke ^a   Yagihashi, Atsuhito ^a   Takahashi, Hiroshi ^b   Watanabe, Naoki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

breast cancer; chromosome 17p13; loss of heterozygosity; p53; survivin; tumor suppressor genes

Indexed keywords

MESSENGER RNA; SURVIVIN;

ADULT; ARTICLE; BREAST CANCER; CANCER TISSUE; CHROMOSOME 17P; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UPREGULATION;

ADULT; AGED; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 4544387381     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000041575.73262.aa     Document Type: Article

References (28)

1. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA: Apoptosis: definition, mechanisms, and relevance to disease. Am J Med 107: 489-506, 1999
2. Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 248: 30-43, 1999
3. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JCL: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998
4. Shin S, Sung BJ, Cho YS, KiM HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123, 2001
5. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997
6. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134, 2000
7. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A: A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104, 1999
8. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998
9. Lu CD, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58: 1808-1812, 1998
10. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46: 645-650, 2000
11. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257, 2002
12. Seitz S, Poppe K, Fischer J, Nothnagel A, Estevez-Schwarz L, Haensch W, Schlag PM, Scherneck S: Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 194: 318-326, 2001
13. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91: 1204-1209, 2000
14. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102, 1999
15. Tsuji N, Kamagata C, Furuya M, Kobayashi D, Yagihashi A, Morita T, Horita S, Watanabe N: Selection of an internal control gene for quantitation of mRNA in colonie tissues. Anticancer Res 22: 4173-4178, 2002
16. Holland PM, Abramson RD, Watson R, Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 88: 7276-7280, 1991
17. Yajima T, Yagihashi A, Kameshima H, Kobayashi D, Furuya D, Hirata K, Watanabe N: Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem 44: 2441-2445, 1998
18. Michalovitz D, Halevy O, Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680, 1990
19. Reihsaus E, Kohler M, Kraiss S, Oren M, Montenarh M: Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 5: 137-145, 1990
20. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988
21. Cesarman E, Inghirami G, Chadburn A, Knowles DM: High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143: 845-856, 1993
22. Matsushima AY, Cesarman E, Chadburn A, Knowles DM: Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 144: 573-584, 1994
23. Kennedy SM, Macgeogh C, Jaffe R, Spurr NK: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 25: 438-442, 1994
24. Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue DP, Parfrey NA: Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 180: 364-370, 1996
25. Ho WL, Chang JW, Tseng RC, Chen JT, Chen CY, Jou YS, Wang YC: Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer. Cancer Detect Prev 26: 343-349, 2002
26. Launonen V, Mannermaa A, Stenback F, Kosma VM, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, Winqvist R: Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet 122: 49-54, 2000
27. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997
28. Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E: Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6: 3103-3110, 2000